Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

14.08
-0.2400-1.68%
Post-market: 14.080.00000.00%19:30 EDT
Volume:265.21K
Turnover:3.74M
Market Cap:1.83B
PE:-31.71
High:14.34
Open:14.34
Low:14.01
Close:14.32
52wk High:21.50
52wk Low:13.05
Shares:129.69M
Float Shares:86.19M
Volume Ratio:1.25
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4440
EPS(LYR):-0.4441
ROE:-9.86%
ROA:-4.11%
PB:3.21
PE(LYR):-31.71

Loading ...

Mesoblast Stock Leads 3 Australian Growth Shares With Strong Earnings Expectations

Simply Wall St.
·
Aug 23

Mesoblast Stock Leads 3 High Growth Insider Owned ASX Shares To Watch

Simply Wall St.
·
Aug 21

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

TIPRANKS
·
Aug 17

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

GlobeNewswire
·
Aug 17

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

TIPRANKS
·
Aug 17

State Street Group Ceases to Be Substantial Holder in Mesoblast

TIPRANKS
·
Aug 07

State Street Group Cuts Mesoblast Stake Below Substantial Holder Threshold

TIPRANKS
·
Aug 03

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

GlobeNewswire
·
Jul 30

Mesoblast - Q4 Ryoncil Net Revenue US$36 Mln

THOMSON REUTERS
·
Jul 30

Mesoblast Stock And 2 Australian Founder Led Companies Worth Watching

Simply Wall St.
·
Jul 27

State Street Exits Substantial Holding in Mesoblast

TIPRANKS
·
Jul 24

Mesoblast CEO Boosts Stake as Company Files New Equity Announcements

TIPRANKS
·
Jul 21

Mesoblast CEO Boosts Stake in Company With AU$2.7 Million Exercise of Options

MT Newswires Live
·
Jul 21

Mesoblast - CEO Exercises 1.9 Mln Options at A$1.45 Each for A$2.73 Mln

THOMSON REUTERS
·
Jul 21

Mesoblast - CEO Increases Shareholding to 80.8 Mln Shares

THOMSON REUTERS
·
Jul 21

Mesoblast Expands Ordinary Share Base Through Conversion of Unquoted Securities

TIPRANKS
·
Jul 14

Mesoblast Seeks ASX Quotation for 2.25 Million Incentive Shares

TIPRANKS
·
Jul 14

Mesoblast Issues 8.2 Million Unquoted Employee Options

TIPRANKS
·
Jul 14

Mesoblast Achieves Patient Treatment Target in Phase 3 Trial of Chronic Lower Back Pain

MT Newswires Live
·
Jul 14

Mesoblast Hits 300‑Patient Milestone in Pivotal Back Pain Trial

TIPRANKS
·
Jul 14